The FDA has approved the first ophthalmic formulation of bevacizumab for wet age-related macular degeneration, closing a gap that has defined retina care for twenty years.
Outlook Therapeutics announced that Lytenava, generic name bevacizumab-vikg, was approved for neovascular age-related macular degeneration. The company expects a U.S. launch before the end of 2026 and anticipates 12 years of reference product exclusivity under the Biologics Price Competition and Innovation Act.
For the roughly 1.5 million Americans living with wet AMD, the immediate clinical change is smaller than the announcement suggests. Most of them are already receiving bevacizumab. What changes is where it comes from and, potentially, what it costs.
A Drug Used for Two Decades Without an Approval for This Use
Bevacizumab was developed as an intravenous cancer drug, sold as Avastin, and it works by blocking vascular endothelial growth factor, a signaling protein that drives the growth of new blood vessels.
Retina specialists recognized almost immediately that the same mechanism should work in the eye, where abnormal vessel growth is the problem in wet AMD. Because no eye-specific version existed, compounding pharmacies began drawing the intravenous product into small syringes sized for injection into the eye. That practice began in 2005 and never stopped.
The result is one of the odder situations in American medicine. Bevacizumab accounts for the majority of first-line anti-VEGF treatment in wet AMD, according to figures cited by Outlook Therapeutics, and until last month none of that use was FDA-approved for the eye.
Company chief executive Bob Jahr said in the approval announcement that bevacizumab has served as "one of the most widely utilized anti-VEGF therapies in retina care" despite the absence of an approved ophthalmic formulation. That framing comes from the manufacturer.
Abnormal Vessels Under the Retina, and What the Injections Do
Age-related macular degeneration affects the macula, the small central portion of the retina responsible for sharp, straight-ahead vision. The dry form is far more common and progresses slowly. The wet form accounts for a minority of cases but the majority of severe vision loss.
In wet AMD, abnormal blood vessels grow beneath the retina and leak fluid and blood. The leakage lifts and distorts the macula, and untreated, it can destroy central vision within months. Peripheral vision generally survives, which is why people with advanced wet AMD can often still navigate a room but cannot read, drive, or recognize faces.
Anti-VEGF injections do not cure this. They suppress the signal driving vessel growth and leakage, and they must be repeated, typically every four to twelve weeks depending on the drug and the patient's response. The injection itself is delivered into the vitreous, the gel filling the eye, after numbing drops.
Treatment works best when it starts early, which is the single most actionable point for readers. Vision lost to untreated leakage is often not recoverable.
Compounding Filled the Gap, with Known Trade-Offs
Compounded bevacizumab has been enormously valuable and carries real limitations, both of which are relevant to what an approved version adds.
A compounding pharmacy splitting one vial of an intravenous drug into dozens of eye-sized doses is performing a sterile manufacturing step outside the FDA-approved manufacturing process for that product. Sterility failures in compounded ophthalmic bevacizumab have caused clusters of endophthalmitis, a serious intraocular infection, on multiple occasions. Batch-to-batch consistency, container closure integrity, and cold chain handling all sit with the compounder rather than with a manufacturer under FDA oversight.
An approved ophthalmic product brings FDA-reviewed manufacturing, approved labeling written for intravitreal use, formal pharmacovigilance, and a defined quality system. That is a genuine safety argument, and it is the strongest case for the approval.
What it does not bring is evidence that the molecule works better. It is the same active ingredient that retina specialists have been using since 2005.
Price Has Not Been Announced, and Exclusivity Is the Open Question
The reason bevacizumab dominates first-line treatment despite the availability of purpose-built anti-VEGF drugs is cost. Compounded doses have historically been dramatically cheaper than branded alternatives, which is what allowed clinics serving Medicare patients and safety-net populations to treat aggressively.
Outlook Therapeutics has not disclosed pricing. It has told investors it is targeting a U.S. retina market it values at roughly $ 8.5 billion and expects 12 years of exclusivity, which are statements about commercial ambition rather than patient cost.
The open question is what happens to the compounded supply. If an FDA-approved ophthalmic bevacizumab exists, pressure may build on compounding pharmacies to stop preparing the off-label version, since federal compounding law generally restricts compounding of a drug that is essentially a copy of a commercially available approved product. Whether that pressure materializes, and how quickly, will determine whether patients see improved safety oversight, an increase in cost, or both.
Medicare Part B covers physician-administered eye injections, and coverage terms for the new product had not been announced as of this writing. Patients should not assume their out-of-pocket cost will change or stay the same. The right time to ask is at the next appointment.
Symptoms That Warrant an Urgent Eye Exam
The warning signs of wet AMD are specific enough to be recognized, and recognizing them early is what preserves vision.
Straight lines appearing wavy or bent, a blurred or blank spot in the center of vision, difficulty reading or recognizing faces, colors appearing less vivid, and needing more light than before are the classic presentations. Sudden distortion or a new central blind spot warrants an eye exam within days rather than at the next routine visit.
Risk rises sharply after 60, and is higher in people who smoke, have a family history of AMD, have high blood pressure or cardiovascular disease, or are white. Smoking cessation is the single largest modifiable risk factor.
Anyone already receiving anti-VEGF injections should keep their existing schedule and raise questions about the new product with their retina specialist rather than requesting a change based on a news report. Missed injections are a well-documented cause of vision loss in this population.
Outlook Therapeutics has said it is preparing reimbursement and patient support programs ahead of launch. MedicalDaily will report on pricing when it is announced and on any change in the availability of compounded bevacizumab.
Frequently Asked Questions
What was approved? Lytenava, generic name bevacizumab-vikg, the first FDA-approved ophthalmic formulation of bevacizumab, for neovascular age-related macular degeneration. The company expects a U.S. launch before the end of 2026.
Is this a new drug? No. Bevacizumab has been injected into eyes off label since 2005 using compounded preparations of the intravenous cancer drug Avastin. This is the first version approved and manufactured specifically for eye use.
Does it work better than what I am getting now? There is no evidence it is more effective. It is the same active ingredient. The difference is FDA-reviewed manufacturing, approved labeling for intravitreal use, and formal safety monitoring.
Will it cost more? Pricing has not been announced. The company anticipates 12 years of market exclusivity, which is a factor worth watching. Ask your retina practice about your specific coverage.
What is wet AMD? A form of age-related macular degeneration in which abnormal blood vessels grow under the retina and leak, damaging central vision. It is less common than the dry form but causes the most severe vision loss.
What symptoms should prompt an urgent visit? Straight lines appearing wavy, a new blurred or blank spot in central vision, or sudden difficulty reading or recognizing faces. These warrant an eye exam within days.
Should I ask to switch products? Keep your current injection schedule and raise the question at your next appointment. Missing injections is a documented cause of vision loss.
